IBRX Immunitybio Inc
Company Analysis
Latest News
🔴 IBRX is trading 6.2% down today amid class action legal overhang and profit taking
IBRX is trading 6.2% down today at $7.24 as investors react to ongoing securities class action reminders and profit taking following recent volatility. •...
🔴 IBRX is trading 5.1% down today amid legal overhangs and profit taking
IBRX is trading 5.1% down today at $7.33 amid ongoing legal overhangs and profit taking following recent volatility. • The decline follows a series of...
🟢 IBRX is trading 10.9% up today as lead-plaintiff deadline for securities class actions approaches
IBRX is trading 10.9% up today at $8.01 as investors react to the May 26, 2026, lead-plaintiff deadline for multiple securities class actions tied to Anktiva...
ImmunityBio's Legal Cloud Lifts Slightly on Deadline Day — But Can the Stock Escape Its Courtroom Overhang?
Shares of ImmunityBio (IBRX) ticked up 3.3% to $7.46 on May 26, 2026 — the very day a critical lead-plaintiff deadline expires in securities fraud class...
🟢 IBRX is trading 3.3% up today as lead-plaintiff deadline for class action hits
IBRX is trading 3.3% up today at $7.46 as investors digest the May 26, 2026, lead-plaintiff filing deadline for ongoing securities class actions. • The stock...
🔴 IBRX is trading 5.6% down today as profit-taking continues after FDA-driven rally
IBRX is trading 5.6% down today at $7.31 as investors continue to lock in gains following a significant rally triggered by the FDA's sBLA acceptance for...
🔴 IBRX is trading 4.2% down today as profit-taking extends after FDA sBLA acceptance rally
IBRX is trading 4.2% down at $7.42 as traders extend profit-taking following the sharp FDA sBLA acceptance rally linked to ANKTIVA plus BCG. • The stock...
🔴 IBRX is trading 6.5% down today on profit-taking after its FDA sBLA acceptance rally
IBRX is trading at $7.53 (-6.52%) as the stock undergoes a sharp pullback following a rally sparked by the FDA’s acceptance of its supplemental BLA for ANKTIVA...
🔴 IBRX is trading 3.9% down today on profit-taking after its FDA sBLA acceptance rally
IBRX is trading 3.9% down at $7.74 today as the stock undergoes profit-taking and consolidation following a sharp rally triggered by positive regulatory...
🟢 IBRX is trading 9.3% up today on FDA acceptance of ANKTIVA sBLA for bladder cancer
IBRX is trading at $8.48 (+9.28%) following the FDA's acceptance of ImmunityBio’s supplemental Biologics License Application (sBLA) for ANKTIVA. • The filing...
🟢 IBRX is trading 7.2% up today after FDA accepts ANKTIVA sBLA for bladder cancer
IBRX is trading 7.2% up at $8.32 in pre-market after the FDA accepted ImmunityBio’s supplemental Biologics License Application (sBLA) for ANKTIVA. • The...
🟢 IBRX is trading 4.5% up today after FDA accepts ANKTIVA expansion filing
IBRX is trading at $8.11 (+4.5%) after the FDA accepted ImmunityBio’s supplemental Biologics License Application (sBLA) for ANKTIVA. • The filing seeks to...
ImmunityBio Jumps, FDA Reviewing ANKTIVA for Major Bladder Cancer Expansion
The FDA accepted ImmunityBio’s supplemental Biologics License Application (sBLA) for ANKTIVA. The application seeks to expand the drug's use in combination...
ImmunityBio ANKTIVA doubles response rates, cuts surgery risk in cancer trial
ImmunityBio announced results from two analyses comparing its bladder cancer treatment, ANKTIVA (NAI) plus BCG, against two FDA-approved therapies. Researchers...
ImmunityBio Enters Exclusive U.S. Supply Agreement for Tokyo Strain of BCG
ImmunityBio, Inc. has entered into an exclusive development and supply agreement with Japan BCG Laboratory (JBL) to address the long-standing shortage of...
ImmunityBio Stock Surges After Securing Five U.S. Patents for Key Cancer Therapy ANKTIVA
ImmunityBio announced the issuance of five U.S. patents for the combination of its cancer treatment ANKTIVA® with Bacillus Calmette-Guérin (BCG). [1, 4] The...
🟢 IBRX is trading 5% up today ahead of key FDA workshop for Anktiva expansion
IBRX is trading 5% up at $8.37 in pre-market ahead of a pivotal FDA workshop for its lead therapy Anktiva, bouncing from last Friday’s $7.97 close after a...
ImmunityBio gains, fueled by Anktiva expansion and new BCG deal
ImmunityBio stock rose 2% in overnight trading. The company faces a May 18, 2026, FDA workshop regarding its lead immunotherapy, Anktiva. This meeting will...
ImmunityBio Faces Investor Class Action Lawsuit Over Alleged Misleading Statements
Bronstein, Gewirtz & Grossman, LLC filed a class-action lawsuit against ImmunityBio, Inc. The suit represents investors who purchased securities between...